Entity Wide Disclosures

12 Months Ended

Dec. 31, 2021

Entity Wide Disclosures [Abstract]

Entity Wide Disclosures

15. ENTITY WIDE DISCLOSURES

Operations By Geographic Location

The Company conducts operations in North America, Europe, Africa, Asia-Pacific and Latin America through wholly-owned subsidiaries and representative sales offices. The Company attributes revenue to geographical locations based upon the location of the contracting entity. For the years ended December 31, 2021, 2020 and 2019, total revenue attributable to the U.S. represented approximately 97%, 96% and 95%, respectively, of total consolidated total revenue.

The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, if any (in thousands):

	2021		2020
Property and equipment, net:
United States	$	64,828	$	58,124
Europe
Belgium		12,339		12,024
Other		8,413		7,961
Total Europe		20,752		19,985
Other		7,573		6,908
Total property and equipment, net	$	93,153	$	85,017

Revenue by Category

The following table disaggregates the Company’s revenue by major source (in thousands):

	Years Ended December 31,
	2021		2020		2019
Therapeutic Area
Oncology	$	362,846	$	297,675	$	256,766
Other		267,415		215,370		196,159
Metabolic		159,900		126,075		138,650
Central Nervous System		121,548		88,393		91,746
Cardiology		119,692		95,153		91,258
AVAI		110,976		103,259		86,390
Total revenue	$	1,142,377	$	925,925	$	860,969